Outcome of pediatric patients with acute myeloid leukemia (AML) and −5/5q− abnormalities from five pediatric AML treatment protocols: A report from the Children's Oncology Group


  • Conflict of interest: Nothing to declare.

Correspondence to: Donna Johnston, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario K1H 8L1, Canada.

E-mail: djohnston@cheo.on.ca



Abnormalities of chromosome 5q (−5/5q−) are associated with poor prognosis in adults with acute myeloid leukemia (AML). However, there are no large studies on outcomes of children with −5/5q− AML. To determine the disease correlates of this group, we retrospectively analyzed cytogenetic data from five studies of childhood AML.


Data from patients whose cytogenetic clones included −5/5q−, with the exception of those with acute promyelocytic leukemia or Down syndrome, were included.


Of the 2,240 patients with cytogenetic data available, 26 (1.2%) had −5 or 5q−. A significant number of these patients were age 11–21 (61.5%, P = 0.031) and had M0 morphology compared with patients without −5/5q− (24.0% vs. 2.8%, P < 0.001). Twenty-two of the 26 patients had a complete remission (CR) response to induction chemotherapy. The 5-year overall survival (OS) from the time of diagnosis for the −5/5q− patients was significantly lower than for patients without −5/5q− (27 ± 17% vs. 50 ± 2%, P = 0.027). Similarly, from induction CR, patients with −5/5q− had significantly worse disease free survival, OS and relapse risk than those without this abnormality (27 ± 19% vs. 46 ± 2%, P = 0.035, 32 ± 20% vs. 57 ± 2%, P = 0.025, 68 ± 21% vs. 45 ± 2%, P = 0.01, respectively).


Pediatric patients with AML and −5/5q− had a very poor outcome. These findings support the need for new or novel therapies for these patients. Pediatr Blood Cancer 2013;60:2073–2078. © 2013 Wiley Periodicals, Inc.